Healthy Clinical Trial
Official title:
Aromatase Activity and Ovarian Growth Factors in Preovulatory Follicles
The purpose of the study is to understand how the ovarian follicle (the fluid filled
structure in the ovary that contains the egg) makes estrogen and other hormones during
normal aging, in women with different ethnic backgrounds, and in Fragile X premutation
carriers.
During reproductive aging, estradiol levels are increased, a phenomenon that may be related
to increased aromatase activity. The investigators' own preliminary data suggest that
estradiol is increased in African-American women compared to Caucasian women, which may also
be related to aromatase activity. In addition, the investigators have examined female
fragile X premutation carriers who still have regular menstrual cycles and have demonstrated
evidence of early ovarian aging compared to age-matched controls.
**WE ARE RECRUITING ONLY WOMEN WITH FRAGILE-X PREMUTATION**
The purpose of the study is to examine intrafollicular changes in aromatase and ovarian
growth factors in reproductive aged women,African-American women compared to Caucasian
controls, and Fragile X premutation carriers.
Hypotheses:
- Aromatase activity is up-regulated in preovulatory follicles with aging, accounting for
the increased estradiol levels in the face of decreased inhibin secretion in
reproductive aging.
- Increased estradiol in the face of normal inhibin A and inhibin B suggests
up-regulation of aromatase in African-American women.
- Aromatase activity is down-regulated in preovulatory follicles in fragile X premutation
carriers compared to age-matched controls and the activity is associated with FMR1 mRNA
levels.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |